Wafik El-Deiry, MD, PhD, FACP

Laboratory of Translational Oncology & Experimental Cancer Therapeutics, Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, USA

Wafik El-Deiry, MD, PhD, FACP is the Deputy Cancer Center Director for Translational Research, co-Leader of the Molecular Therapeutics Program, Professor of Oncology, and the William Wikoff Smith Endowed Chair in Cancer Research at Fox Chase Cancer Center in Philadelphia. Until September 2014 he was the Rose Dunlap Professor of Medicine and Chief of Hematology-Oncology at Penn State University. In 2009, El-Deiry became one of 40 active American Cancer Society Research Professors. He earned MD/PhD degrees from University of Miami School of Medicine and completed internal medicine residency and medical oncology fellowship at Johns Hopkins.

He discovered cyclin-dependent kinase (CDK) inhibitor p21(WAF1) as a p53 target gene and cell cycle inhibitor that explained the mammalian cell stress response. This work published in 1993 is the most highly cited original work published in Cell. El-Deiry joined University of Pennsylvania School of Medicine in 1994 rising to Professor of Medicine, Pharmacology and Genetics in 2005 and was a Howard Hughes Medical Institute Investigator from 1995-2004. He served as co-Leader of the Radiobiology & Imaging Program at the Abramson Cancer Center from 2004-2010. El-Deiry made important contributions in cell death signaling including discovery of TRAIL receptor DR5 as a p53 target and mediator of extrinsic cell death after DNA damage. He discovered and brought first-in-class TRAIL-pathway activating small-molecule ONC201/TIC10 into clinical trials for patients with cancer. El-Deiry is a well-funded and productive physician-investigator who has >400 peer-reviewed publications and 5 edited books. In 2017 his H-index is 109 and he has nearly 61,000 citations in Google Scholar. He is a member of the Interurban Clinical Club (President 2013-2014), American Society for Clinical Investigation (1999-) and Association of American Physicians (2008-). He won the Michael Brown Award from University of Pennsylvania (1998), the Elizabeth and John Cox Award from Georgetown (2005), the 2009 Kuwait Prize for "Cancer Diseases." El-Deiry is an elected member of the Johns Hopkins University Society of Scholars (2014-). He specializes in the care of patients with colorectal cancer, patients with rare genetic drivers of other tumor types at Fox Chase where he conducts his preclinical and clinical therapeutics research.

In 2017, he serves as the Chair of an NIH Study Section on molecular targets and basic mechanisms of cancer therapeutics (BMCT-C), as the Track Leader for Tumor Biology (ASCO), as a member of the American Cancer Society (ACS) Council for Extramural Grants and as a Member of the Conquer Cancer Foundation Review Board (ASCO). In addition to his research and clinical activities, Dr. El-Deiry has trained many and continues to mentor junior scientists and faculty in basic and translational cancer research.